GlycoMimetics (NSDQ:GLYC) priced an underwritten public offering of 7,000,000 shares of common stock at $17.00 apiece today, reporting that it expects to bring in $119 million from the offering.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finish facility located in Baltimore, Md. The multi-year expansion is expected to be completed in 2021, and will significantly increase the company’s contract development and manufacturing capacity, redundancy, and flexibility. This expansion is also anticipated to create up to 60 new jobs in the next three years.
The company will receive $75,000 in exchange for up to 10 percent equity, plus incubation space and a customized growth strategy.
Instem, a leading provider of IT solutions to the global life sciences market, is pleased to announce that Noble Life Sciences, Inc. (Noble) has purchased a comprehensive package of preclinical software solutions, including Provantis®, the market leading preclinical data management system.
Fifteen children born with a rare muscle-wasting disease would probably not be alive today if not for an experimental treatment that tweaked their genes shortly after they were born.
Servier, an independent international pharmaceutical company, today announced the appointments of Christian Schubert, Ph.D. and Rekha Paleyanda, Ph.D., as Directors of Servier BioInnovation along with the opening of the Servier BioInnovation office in Cambridge, Massachusetts. The appointments of Dr. Schubert and Dr. Paleyanda, who will head Servier’s U.S. R&D and external innovation, and business development and licensing (BD&L) activities respectively, will operationalize the launch of Servier BioInnovation in the U.S. Located in the heart of one of the world’s leading biotechnology hubs in the Cambridge Innovation Center at Kendall Square, Servier BioInnovation will lead Servier’s expansion efforts into the U.S. innovation ecosystem.
New York City-based pharmaceutical company Pfizer Inc is planning on investing $600 million in biotechnology and other emerging growth companies through Pfizer Ventures. About 25 percent of the funding will focus on neuroscience.
The bioscience industry represents the unique confluence of key characteristics for societal and economic progress—extremely high levels of innovation that are saving and improving lives through advancements in biomedical, energy and advanced food and industrial technologies; and expanding a wide mix of employment opportunities with wages and incomes that support a high standard of living. The industry thinks big and is addressing a host of global grand challenges related to diagnosing, treating and curing disease; ensuring a safe, affordable and more sustainable food supply; and leveraging biotechnologies and sustainable approaches to develop biobased fuels, chemicals and other industrial products.
Last week, SSTI examined the geography of “America’s Seed Fund,” the SBIR/STTR awards, on a state-by-state basis. A look at how the more than 25,500 awards were distributed at the regional level over the five-year period from 2013 to 2017 yields additional insight. The metropolitan areas with the largest concentrations of SBIR/STTR awards include knowledge hubs with large universities and access to federal R&D, such as Boston, Los Angeles, and Washington D.C. Smaller regions with a large federal R&D presence, like Huntsville, Alabama, Santa Maria, California and Dayton, Ohio also rank highly.
Sonavex, Inc., a privately held medical device company focused on improving surgical patient outcomes with point-of-care imaging technologies, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EchoMark and EchoMark LP soft tissue markers.